

# International Conference on Alzheimer's disease and Dementia

Date and Venue: August 31 - September 02, 2015 Toronto, Canada

**Theme:** Diagnosis Approaches of Dementia and Alzheimer's disease

## About the Conference:

Dementia2015 welcomes attendees, presenters, and exhibitors from all over the world to Toronto, Canada. We are delighted to invite you all to attend and register for the "3rd International Conference on Alzheimer's disease and Dementia (Dementia2015)" which is going to be held during August 31 - September 02, 2015 Toronto, Canada.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia2015, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia2015 organizing committee look forward to meeting you in Toronto, Canada. (Body Text First Indent)

For more details please visit- <http://alzheimers-dementia.conferenceseries.com/>

## Importance & Scope:

Dementia is a general term that describes a group of symptoms-such as loss of memory, judgment, language, complex motor skills, and other intellectual function-caused by the permanent damage or death of the brain's nerve cells, or neurons.

Dementia, including Alzheimer's disease, is one of the biggest global public health challenges facing our generation.

Globally, results of a recent meta-analysis suggest that 35.6 million people lived with dementia worldwide in 2010, with numbers expected

to almost double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 percent of all people with dementia lived in countries with low or middle incomes, with this proportion anticipated to rise to 63 percent in 2030 and 71 percent in 2050. This number is expected to double by 2030 and more than triple by 2050 to 115 million.

In the United States alone, experts estimate that as many as five million people age 65 and older suffer from Alzheimer's disease.

## Why in Toronto, Canada?


According to the Canada government, an estimated 747,000 Canadians were living with Alzheimer's disease or other forms of dementia in 2011.

In Canada 72% of Alzheimer's sufferers are women and 62% of dementia cases are also women. Much of the increase will be in developing countries like Western Europe and North America. Already 62% of people with dementia live in developing countries.

Nearly 800,000 Canadians are currently living with Alzheimer's disease or other forms of dementia. By 2031, that number will likely double.


In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost \$300 billion per year.

## People with Dementia in Toronto



**Figure 1:** Statistical Analysis of People with Dementia in Toronto

## People with Dementia in Canada



**Figure 2:** Statistical Analysis of People with Dementia in Canada

Toronto is Canada's largest city, the fourth largest in North America, and home to a diverse population of about 2.8 million people. It's a global center for business, finance, arts and culture and is consistently ranked one of the world's most livable cities. The Greater Toronto Area (GTA) is a modern multicultural urban center with something for everyone. Year round, the GTA offers a unique mix of historical attractions, seasonal celebrations, family fun and a safe, walkable downtown core.

### Conference Highlights:

- Fast Facts: Dementia
- Dementia Causes, Concerns and Preventions
- Managing Dementia
- Dementia Medication
- Clinical Trials & Case Study
- New Drug Discovery: Animal Models and Translational Research
- Managing Dementia
- Dementia Medication
- Clinical Trials & Case Study
- Clinical Trials & Case Study

### Why to attend???

Dementia-2015 will provide an opportunity for all stakeholders working on Alzheimer's disease and Dementia to talk about their work. Dementia- 2015 will congregate renowned speakers, principal investigators, experts, neurologists and Dementia researchers from both academia and health care industry will join together to discuss their views and research. The conference will be comprised of sessions by world class experts in the field of neurology. In Euro Psychiatry Summit-2015, international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Dementia and Neurology.

A Unique Opportunity for Advertisers and Sponsors at this International event:

[http://omicsgroup.com/conferences/ACS/conference/pdfs/dementia2015\\_Sponsorship.pdf](http://omicsgroup.com/conferences/ACS/conference/pdfs/dementia2015_Sponsorship.pdf)

### Members Associated with Dementia

Canadian Consortium on Neurodegeneration in Aging (CCNA) it brings together 340 researchers from across the country.

Their research will focus on improving the quality of life of those already living with Alzheimer's disease and other forms of dementia.

The consortium is supported with funding of \$31.5 million over five years from the Government of Canada through the Canadian Institutes of Health Research and a group of 13 partners from the public and private sectors, including the Alzheimer Society of Canada and Fonds de recherche du Québec – Santé.

Jewish General Hospital (Montreal)

University of Ottawa

Mount Sinai Hospital-TORONTO

University of Alberta

McGill University

The Canadian Institutes of Health Research

Canadian Consortium on Neurodegeneration in Aging (CCNA)

Hospitals Associated with Dementia

### About 200 Organizations Providing Dementia Services in Toronto

Mount Sinai

A.G.E. Matters Clinic

Ability Health Care Supplies

Comforcare Toronto Central

Craig lee Nursing Home


Distress Centers of Toronto  
 Eatonville Care Centre  
 Eldercare Home Health Inc.  
 Fairview Nursing Home

Alzheimer's disease Chinese  
 Alzheimer Association & Societies in Canada  
 Alzheimer Society of Ontario  
 Alzheimer's disease International  
 Dementia Networks across Ontario  
 Alzheimer's Education and Referral Center  
 Alzheimer Research Forum  
 Alzheimer Knowledge Exchange  
 Murray Alzheimer Research and Education Program (MAREP)  
 University of Waterloo  
 Universities in Canada:  
 University of Toronto  
 University of British Columbia  
 University of Alberta  
 Simon Fraser University  
 University of Waterloo  
 McGill University  
 University of Calgary  
 Queen's University  
 York University  
 University of Victoria

**Alzheimer Association & Societies around the Globe**

Alzheimer's Australia  
 Albanian Alzheimer Society  
 Asociación de Lucha contra el Mal de Alzheimer  
 Asociación de Lucha contra el Mal de Alzheimer  
 Fundacion Alzheimer Aruba (FAA)  
 Alzheimer's Australia  
 Alzheimer Austria  
 Alzheimer Support Group  
 Alzheimer Society of Bangladesh  
 Barbados Alzheimer's Association Inc.  
 Alzheimer's and Dementia Association of The Cayman Islands  
 Ligue National Alzheimer Liga  
 Alzheimer's Family Support Group  
 Asociación Boliviana de Alzheimer y Otras Demencias  
 FEBRAZ - Federação Brasileira de Associações de Alzheimer  
 Corporation Alzheimer Chile

Universities associated with dementia in globally



**Figure 4:** Universities associated with dementia

## Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia

## Market Value and Growth on Dementia:

Economic cost of dementia in Canada 2011 \$33 billion

Globally, dementia cost \$600 billion in a year

In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost \$300 billion per year

From 2003-2013 CIHR funding for dementia research was \$236 million

The Pfizer drug dominates sales, with about \$ 4 billion annually

Aricept (Donepezil-generic) (Pfizer)

Ranbaxy market size of Aricept (Donepezil Hydrochloride) in Canada is \$ 153.9 million

Razadyne (Johnson & Johnson) market size is \$ 5.3 billion

Exelon (Novartis)

Namenda (Forest Laboratories) spending for dementia research was \$236 million

## Products manufactured by the industries

Three drugs are available in Canada to treat symptoms in people with Mild to moderate Alzheimer's disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer's disease

Ebixa®

Aricept™

## Alzheimer's disease and Dementia in numbers...

60150	1 in 3	1 in 5
New cases of dementia each year in Canada	Seniors dies with Alzheimer's or another dementia	Baby-boomers will develop Alzheimer's disease in their lifetime
17140	1 in 11	5
Quebecers living with Alzheimer's disease or a related dementia are under age 65	Canadians over the age of 65 are affected by Alzheimer's disease, the most common form of dementia	Every 5 minutes, someone is diagnosed with Alzheimer's disease and/or related disorders
0.33	0.2	0.25
Of all Canadians know somebody who has Alzheimer's disease	Of Canadians have a family member who has Alzheimer's disease	Less than 25% of cases of Alzheimer's disease in Canada are diagnosed and treated
20	\$15 billion	\$153 billion
Alzheimer's begins about 20 years before symptoms appear	Current costs of Alzheimer's disease per year	Yearly costs of Alzheimer's disease in 2038

## Fund Allotment to Dementia

National dementia research initiative gets \$31.5M funding from the federal government and several partners, as well as an additional, separate \$24 million from partners in Ontario and Quebec. In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost \$300 billion per year.

Alberta Prion Research Institute	\$150,000
Alzheimer's Research UK	\$300,000
Alzheimer Society of Canada	\$4,050,000
Canadian Institutes of Health Research	\$21,650,000
Canadian Nurses Foundation	\$50,000
Fonds de recherche du Québec Santé Pfizer Canada	\$5,000,000
Michael Smith Foundation for Health Research	\$ 400,000
New Brunswick Health Research Foundation	\$1,080,000
Nova Scotia Health Research Foundation	\$125,000
Ontario Brain Institute	\$19,000,000
Robin and Barry Picov Foundation	\$500,000
Sanofi	\$2,500,000
Saskatchewan Health Research Foundation	\$500,000
Women's Brain Health Initiative	\$250,000

## References:

- <http://www.cihr-irsc.gc.ca/e/45554.html>
- <http://www.providencecare.ca/clinical-tools/Documents/Ontario-Dementia-Projections-2010.pdf>
- <http://www.concordia.ca/cunews/main/stories/2014/09/16/revolutionizingalzheimersresearchincanada.htm>
- <http://www.dementiatoronto.org/allagencies.asp>
- <http://www.cbc.ca/news/health/national-dementia-research-initiative-gets-31-5m-federal-funding-1.2762253>
- <http://seekingalpha.com/article/2042953-following-the-latest-in-alzheimers-research-as-an-investor>
- <http://www.alzheimer.ca/en/Living-with-dementia/Treatment-options/Drugs-approved-for-Alzheimers-disease>
- <http://news.gc.ca/web/article-en.do?sessionId=a0a6a2037001e091ddee53f66c5dc11c8e26df830028d1e9d682dde6c1b6ecd8.e38RbhaLb3qNe38Kbxj0?mthd=tp&crtr.page=3&nid=883019&crtr.tp1D=1>
- <http://www.jghfoundation.org/sections/vpadd.html>